Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
April 01, 2024 08:30 ET
|
Surrozen, Inc.
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
Cirrhosis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight
March 25, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, March 25, 2024 (GLOBE NEWSWIRE) -- Cirrhosis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight The rise in the number of people suffering from cirrhosis can be...
Global Human Liver Models Market to 2028: Featuring Ascendance Biotechnology, CN Bio Innovations, Cyfuse Biomedical, Emulate and Organovo Holdings Among Others
February 21, 2023 13:03 ET
|
Research and Markets
Dublin, Feb. 21, 2023 (GLOBE NEWSWIRE) -- The "Human Liver Models - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Human Liver...
Non-Alcoholic Steatohepatitis (NASH) Market Worth $24.26Bn, Globally, by 2028 at 47.1% CAGR - Exclusive Report by The Insight Partners
May 04, 2022 08:37 ET
|
The Insight Partners
New York, May 04, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028 - COVID-19 Impact and Global Analysis...
Inventiva annonce la présentation de cinq abstracts scientifiques lors du The Liver Meeting™ 2021 organisé par l’AASLD
October 18, 2021 16:00 ET
|
INVENTIVA
Quatre présentations par poster confirment les effets bénéfiques de lanifibranor sur des composants clés de la NASH faisant suite à des analyses supplémentaires réalisées sur les résultats de l'étude...
Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021
October 18, 2021 16:00 ET
|
INVENTIVA
Four poster presentations add to the evidence of the beneficial effects of lanifibranor therapy on key components of NASH, following further sub-analyses of Inventiva’s NATIVE Phase IIb clinical trial...
Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C
March 22, 2021 16:01 ET
|
Akero Therapeutics
-- 33% of patients treated with efruxifermin (EFX) (4 of 12) improved by one fibrosis stage without worsening of NASH -- -- 25% of EFX patients (3 of 12) showed NASH resolution -- --...
Akero Therapeutics to Announce New Data from an Evaluation of Efruxifermin (EFX) in Cirrhotic NASH (F4) Patients
March 22, 2021 06:30 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
Global Liver Institute Offering Multilingual Materials and Grants for International NASH Day on June 10
March 04, 2021 09:24 ET
|
Global Liver Institute
Washington, DC, March 04, 2021 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI) is pleased to announce that the 2021 International NASH Day (#NASHday) will be held on June 10, 2021, with the theme,...
Surrozen Awarded NIH Grant to Support Development of SZN-043, a Liver-Specific Regenerative Antibody, for the Treatment of Severe Alcoholic Hepatitis
October 15, 2020 07:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, has been awarded an NIH grant to...